 |
|
|
| |
Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 72 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449)
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Maggiolo F, RizzardiniG, Molina JM, Pulido F, De Wit S, VandekerckhoveL, BerenguerJ,Blair C, Chuck S, PiontkowskyD, Martin H, McNichollI, HaubrichR, Gallant J
Gilead Sciences, Inc., Foster City, California, USA
|
| |
|
|
|
|
|
